Close Menu

NEW YORK (GenomeWeb News) – Clarient today said that it has licensed from Minerva Biotechnologies exclusive rights to develop and commercialize a test that identifies the MUC1* protein, a biomarker that researchers believe may be associated with the spread of several cancers.

Clarient believes the biomarker could be used for diagnosis, therapy selection, and monitoring of drug effectiveness in solid tumors. Aliso Viejo, Calif.-based Clarient expects a further year of development to thoroughly evaluate the predictive value of measuring MUC1* in a patient's sample.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.